Voriconazole 투여 중 발생한 환시 및 환청 1례
A Case of Visual and Auditory Hallucinations during Intravenous Voriconazole Therapy
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Voriconazole is a triazole with broad spectrum antifungal activity, and it is currently considered to be the first-line agent for the treatment of invasive aspergillosis. We report here on a case of visual and auditory hallucinations during intravenous treatment with voriconazole in association with a high trough level. A 28-year-old man with acute myelogenous leukemia was admitted for re-induction remission chemotherapy. During the persistent neutropenic fever, intravenous voriconazole was administered for the suspected invasive fungal pneumonia. He began to have visual hallucinations on the 1st day and auditory hallucinations on the 3rd day of voriconazole therapy. The plasma peak and trough concentration levels of voriconazole were 9.9 and 7.4 μg/ml, respectively, on the 3rd day. The hallucinations resolved after changing to amphotericin B deoxycholate, and the plasma concentration of voriconazole dropped to less than 0.5 μg/ml. The genotype of the CYP2C19 alleles was classified as a heterozygous extensive metabolizer. We suggest that therapeutic drug monitoring of voriconazole is indicated for a case that is suspicious for a voriconazole-related adverse event.
Abstract
Voriconazole is a triazole with broad spectrum antifungal activity, and it is currently considered to be the first-line agent for the treatment of invasive aspergillosis. We report here on a case of visual and auditory hallucinations during intravenous treatment with voriconazole in association with a high trough level. A 28-year-old man with acute myelogenous leukemia was admitted for re-induction remission chemotherapy. During the persistent neutropenic fever, intravenous voriconazole was administered for the suspected invasive fungal pneumonia. He began to have visual hallucinations on the 1st day and auditory hallucinations on the 3rd day of voriconazole therapy. The plasma peak and trough concentration levels of voriconazole were 9.9 and 7.4 μg/ml, respectively, on the 3rd day. The hallucinations resolved after changing to amphotericin B deoxycholate, and the plasma concentration of voriconazole dropped to less than 0.5 μg/ml. The genotype of the CYP2C19 alleles was classified as a heterozygous extensive metabolizer. We suggest that therapeutic drug monitoring of voriconazole is indicated for a case that is suspicious for a voriconazole-related adverse event.
참고문헌 (20)
- Herbrecht R, "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", N Engl J Med, 347, pp.408~415 (2002)
- Boyd AE, "Adverse reactions to voriconazole", Clin Infect Dis, 39, pp.1241~1244 (2004)
- 권재철, "국내 혈액질환 환자에서 침습성 아스페르길루스증의 구제치료로서 Voriconazole의 효과와 안전성", Infection and Chemotherapy, 42(1), pp.17~22 (2010), 대한감염학회
- Zonios DI, "Hallucinations during voriconazole therapy", Clin Infect Dis, 47, pp.e7~e10 (2008)
- Miyakis S, "Voriconazole concentrations and outcome of invasive fungal infections", Clin Microbiol Infect, 16, pp.927~933 (2010)
- Pascual A, "Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes", Clin Infect Dis, 46, pp.201~211 (2008)
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30, pp.239~245 (1981)
- "Briefing document for voriconazole"[URL]
- Brüggemann RJ, "Therapeutic drug monitoring of voriconazole", Ther Drug Monit, 30, pp.403~411 (2008)
- Agrawal AK, "Voriconazole-induced musical hallucinations", Infection, 32, pp.293~295 (2004)
- Pasqualotto AC, "Voriconazole therapeutic drug monitoring: focus on safety", Expert Opin Drug Saf, 9, pp.125~137 (2010)
- Ikeda Y, "Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status", Clin Pharmacol Ther, 75, pp.587~588 (2004)
- Shi HY, "Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism", Eur J Clin Pharmacol, 66, pp.1131~1136 (2010)
- Roh HK, "CYP2C19 genotype and phenotype determined by omeprazole in a Korean population", Pharmacogenetics, 6, pp.547~551 (1996)
- 손영해, "위식도역류질환에서 CYP2C19 다형성과 Helicobacter pylori 유무에 따른 Omeprazole의 위산분비 억제능 변화", 대한소화기학회지, 48(3), pp.162~171 (2006), 대한소화기학회
- Jeong Hoon Lee, "The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole", Gut and Liver, 4(2), pp.201~206 (2010), 거트앤리버 발행위원회
- Hyland R, "Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole", Drug Metab Dispos, 31, pp.540~547 (2003)
- Blume H, "Pharmacokinetic drug interaction profiles of proton pump inhibitors", Drug Saf, 29, pp.769~784 (2006)
- Boparai V, "Guide to the use of proton pump inhibitors in adult patients", Drugs, 68, pp.925~947 (2008)
- Li XQ, "Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities", Drug Metab Dispos, 32, pp.821~827 (2004)